Avivagen OxC-beta is a proprietary concentrated source of oxidized derivatives of beta-carotene that occur extensively in the plant world in minute amounts. The Avivagen OxC-beta compound has a wide range of health benefits and could offer pig and poultry producers an alternative to antibiotics. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function and inflammatory responses, which can result in general overall health improvement, with specific benefits including, for example, better growth, utilization of feed and decreased mortality in poultry and swine. In clinical trials where swine and poultry were given Avivagen OxC-beta instead of antibiotics, swine showed a significant improvement of 8 percent in feed conversion efficiency as well as an 8 percent increase in daily weight gain, while poultry showed a growth effect of 3 to 4 percent. Avivagen’s research has established that many of the health properties associated with so-called carotenoid antioxidants are not derived from their antioxidant properties, but rather from previously undiscovered bio-polymer compounds that arise when carotenoids spontaneously oxidize. This is believed to apply to carotenoids such as beta-carotene, lutein, lycopene, astaxanthin from the 600-odd members of the carotenoid family. Avivagen has determined that these naturally-occurring oxidized carotenoid compounds can work with animals’ immune systems to optimize overall health and well-being. Further clinical trials on OxC-beta’s livestock applications are currently ongoing in Asia.